Cancer targeted therapy strategy based on stem cells
Through CRISPR-Cas9 technology, stem cells are gene edited and cancer cell-specific genes are introduced to identify and kill them in the cancer cell microenvironment, solving the problems of insufficient targeting and major side effects in the existing technology, and achieving high efficiency Safe cancer treatment.
Patent Information
- Application Number
- CN202410945668.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-26
AI Technical Summary
Existing cancer treatment methods are difficult to accurately distinguish healthy cells from cancer cells, resulting in large side effects and strong drug resistance, and the long-term survival rate of patients has not significantly improved.
Gene editing of human mesenchymal stem cells through CRISPR-Cas9 technology, introducing cancer cells to specifically recognize receptor genes and cytotoxic factor genes, allowing stem cells to accurately identify and kill cancer cells in the cancer cell microenvironment and introduce suicide genes To improve safety.
Highly accurate targeted cancer cell therapy is achieved, which significantly improves targeting and safety, provides continuous anti-cancer effects, and enhances the durability and effectiveness of the treatment.
Smart Images

Figure CN119015314A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of targeted therapy, and more particularly to a cancer targeted therapy strategy based on stem cells. Background Art
[0002] In modern medicine, cancer treatment still faces many challenges, despite the existence of a variety of treatment methods such as surgery, radiotherapy, chemotherapy and immunotherapy. These methods have their own advantages, but also have obvious limitations, such as damage to normal cells and recurrence or drug resistance after treatment. In order to improve the accuracy of treatment and reduce side effects, researchers have been seeking more precise treatment strategies.
[0003] Although current cancer treatments have made significant progress, there are still problems with insufficient targeting and potential damage to healthy cells. Traditional treatments often cannot fully distinguish between healthy cells and cancer cells, resulting in high side effects during treatment. In addition, existing treatment options often face the challenge of cancer cells' strong adaptability and easy drug resistance, which limits the effectiveness of treatment and fails to significantly improve patients' long-term survival rate.
[0004] Therefore, in response to the above technical problems, it is necessary to provide a stem cell-based cancer targeted treatment strategy. Summary of the invention
[0005] The purpose of the present invention is to provide a cancer targeted treatment strategy based on stem cells to solve the above problems.
[0006] In order to achieve the above purpose, the technical solution provided by an embodiment of the present invention is as follows:
[0007] A stem cell-based cancer targeted therapy strategy comprises the following steps:
[0008] S1: Select and extract human mesenchymal stem cells with high proliferation capacity and stable gene expression as stem cells for gene editing;
[0009] S2: Use CRISPR-Cas9 technology to introduce cancer cell-specific recognition receptor genes and cytotoxic factor genes into stem cells. Cancer cell-specific recognition receptor genes encode receptors that can recognize cancer cell-specific surface proteins and cytotoxic factor genes. Cytotoxic factor genes are activated in the specific microenvironment of cancer cells.
[0010] S3: Apply edited stem cells to cancer patients to achieve targeted recognition and killing of cancer cells;
[0011] S4: The introduced stem cells activate the built-in proliferation and cytotoxic programs by interacting with specific signals in the cancer cell microenvironment, such as hypoxia or specific cytokines, thereby enhancing the therapeutic effect.
[0012] As a further improvement of the present invention, when selecting the stem cells in step S1, they are screened by specific biomarkers, such as CD44 or CD133, to ensure their survival in the cancer microenvironment.
[0013] As a further improvement of the present invention, the selection of cancer cell specific recognition receptor genes in step S2 is based on whole genome expression analysis to determine those cancer cell surface proteins that are highly expressed in various cancer tissues and lowly expressed in normal tissues.
[0014] As a further improvement of the present invention, the toxin or protein encoded by the cytotoxic factor gene in step S2 is activated only under specific cancer cell microenvironment conditions, such as low pH or high activation factor concentration, to minimize damage to normal cells.
[0015] As a further improvement of the present invention, step S2 further includes using CRISPR-Cas9 technology to knock out genes in stem cells that are known to cause tumor formation or reduce treatment effects, so as to improve the safety and effectiveness of treatment.
[0016] As a further improvement of the present invention, step S2 further includes biosafety-enhanced editing of stem cells, including introducing suicide genes through gene editing technology, which can be triggered by external signals under specific conditions, such as light of a specific wavelength or chemicals, to ensure that the function of stem cells can be safely terminated after treatment or in any abnormal proliferation situation.
[0017] As a further improvement of the present invention, after the stem cells in step S3 are gene-edited, it is necessary to verify the cancer cell recognition and killing efficiency in vitro, including a comprehensive evaluation of the specificity and cytotoxic effects of the edited cells on different cancer cell lines.
[0018] As a further improvement of the present invention, in step S3, the edited stem cells are used in combination with one or more immune enhancers to enhance the immune system's recognition and clearance of cancer cells. The immune enhancers may include but are not limited to checkpoint inhibitors, cytokines or specific antibodies.
[0019] As a further improvement of the present invention, after the introduced stem cells in step S4 are verified to be effective, efficacy and safety tests are performed in animal models, and the test content includes the evaluation of the migration, localization, proliferation and long-term survival ability of the cells in vivo.
[0020] As a further improvement of the present invention, the interaction between stem cells and the cancer cell microenvironment in step S4 is not limited to hypoxia or specific cytokines, but also includes responses to unique metabolites released by cancer cells. These metabolites, such as lactate and growth factors, can serve as activation signals to further activate proliferation and cytotoxic programs in stem cells.
[0021] Compared with the prior art, the advantages of the present invention are:
[0022] This program provides a stem cell-based cancer targeted therapy strategy, which achieves highly precise cancer cell targeting by using CRISPR-Cas9 technology to perform gene editing on human mesenchymal stem cells. By introducing specific cancer cell recognition receptor genes and cytotoxic factor genes, stem cells can accurately identify and selectively kill cancer cells while having little effect on normal cells. By introducing suicide genes, the safety of treatment is increased, so that the activity of stem cells can be quickly terminated under abnormal circumstances. This not only significantly improves the targeting and safety of treatment, but also may provide sustained anti-cancer effects in the body through the migration and proliferation ability of stem cells, greatly enhancing the durability and effectiveness of treatment, and providing a new direction for cancer treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a schematic diagram of a stem cell-based cancer targeted therapy strategy of the present invention. DETAILED DESCRIPTION
[0024] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention; it is obvious that the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments, and all other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making creative work are within the scope of protection of the present invention.
[0025] Example:
[0026] See also Figure 1 , a stem cell-based cancer targeted therapy strategy, comprising the following steps:
[0027] S1: Select and extract human mesenchymal stem cells with high proliferation capacity and stable gene expression as stem cells for gene editing;
[0028] S2: Use CRISPR-Cas9 technology to introduce cancer cell-specific recognition receptor genes and cytotoxic factor genes into stem cells. Cancer cell-specific recognition receptor genes encode receptors that can recognize cancer cell-specific surface proteins and cytotoxic factor genes. Cytotoxic factor genes are activated in the specific microenvironment of cancer cells.
[0029] S3: Apply edited stem cells to cancer patients to achieve targeted recognition and killing of cancer cells;
[0030] S4: The introduced stem cells activate the built-in proliferation and cytotoxic programs by interacting with specific signals in the cancer cell microenvironment, such as hypoxia or specific cytokines, thereby enhancing the therapeutic effect.
[0031] Among them, this program provides a stem cell-based cancer targeted treatment strategy, which achieves highly precise cancer cell targeting by using CRISPR-Cas9 technology to perform gene editing on human mesenchymal stem cells. By introducing specific cancer cell recognition receptor genes and cytotoxic factor genes, stem cells can accurately identify and selectively kill cancer cells while having little effect on normal cells. By introducing suicide genes, the safety of treatment is increased, so that the activity of stem cells can be quickly terminated under abnormal circumstances, which not only significantly improves the targeting and safety of treatment, but also may provide sustained anti-cancer effects in the body through the migration and proliferation ability of stem cells, greatly enhancing the durability and effectiveness of treatment, and providing a new direction for cancer treatment.
[0032] When selecting stem cells in step S1, they are screened by specific biomarkers, such as CD44 or CD133, to ensure their survival in the cancer microenvironment.
[0033] The selection of cancer cell-specific recognition receptor genes in step S2 is based on whole genome expression analysis to identify cancer cell surface proteins that are highly expressed in multiple cancer tissues and lowly expressed in normal tissues. The toxins or proteins encoded by the cytotoxic factor genes in step S2 are only activated under specific cancer cell microenvironment conditions, such as low pH or high activating factor concentrations, to minimize damage to normal cells. Step S2 further includes using CRISPR-Cas9 technology to knock out genes in stem cells that are known to induce tumor formation or reduce therapeutic effects, so as to improve the safety and effectiveness of treatment. Step S2 further includes biosafety-enhanced editing of stem cells, including introducing suicide genes through gene editing technology, which can be triggered by external signals under specific conditions, such as light of a specific wavelength or chemicals, to ensure that the function of the stem cells can be safely terminated after treatment or in any abnormal proliferation situation.
[0034] Among them, step S2 covers multiple key gene editing operations, aiming to improve the accuracy and safety of treatment. The selection of cancer cell-specific recognition receptor genes is based on whole genome expression analysis, which can help identify specific cancer cell surface proteins that are expressed in large quantities in various cancer tissues but almost not expressed in normal tissues. After selecting these markers with significant expression differences, the genes encoding these receptors are introduced into stem cells through CRISPR-Cas9 technology, so that these stem cells can accurately recognize and target cancer cells in vivo.
[0035] The toxins or proteins encoded by the selected cytotoxic factor genes are then designed to be activated only under microenvironmental conditions that are unique to cancer cells, such as low pH or high concentrations of the activating factor. This design reduces potential damage to normal cells because these conditions do not normally occur in healthy tissues.
[0036] In addition, step S2 also includes the use of CRISPR-Cas9 technology to knock out genes in stem cells that may cause tumor formation or reduce the therapeutic effect, such as certain cancer-promoting genes or genes that inhibit cell apoptosis, further enhancing the safety and long-term sustainability of the treatment.
[0037] Finally, to add a safety switch, step S2 also includes biosafety-enhanced editing of stem cells by introducing “suicide genes” that can be triggered by external signals under specific conditions, such as light of a specific wavelength or the addition of chemicals. If any abnormal proliferation or other unforeseen events occur during treatment, the activity of the stem cells can be quickly and safely terminated, thereby protecting the patient from potential risks.
[0038] Through these comprehensive gene editing measures, this treatment strategy can not only efficiently target and eliminate cancer cells, but also greatly improve the safety and controllability of treatment, which will greatly improve the effectiveness of cancer treatment and the quality of life of patients.
[0039] After gene editing, the stem cells in step S3 need to be verified in vitro for cancer cell recognition and killing efficiency, including a comprehensive evaluation of the specificity and cytotoxic effects of the edited cells on different cancer cell lines. In step S3, the edited stem cells are used in combination with one or more immunoenhancers to enhance the immune system's recognition and clearance of cancer cells. Immunoenhancers may include but are not limited to checkpoint inhibitors, cytokines or specific antibodies.
[0040] Among them, the main purpose of step S3 is to ensure that the gene-edited stem cells can effectively identify and eliminate target cancer cells in an in vitro environment. The stem cells edited by CRISPR-Cas9 technology will be tested on a variety of cancer cells to evaluate their recognition specificity and killing efficiency for different types of cancers. These cancer cells represent the biological characteristics of various cancers, including but not limited to breast cancer, lung cancer, skin cancer, etc. In this way, it is possible to monitor in detail whether the stem cells can accurately target cancer cells and effectively induce the death of cancer cells without damaging normal cells.
[0041] In order to enhance the therapeutic effect, step S3 also includes using the gene-edited stem cells in combination with one or more immunopotentiators. The function of these immunopotentiators is to activate or enhance the patient's own immune system so that it can more effectively identify and eliminate cancer cells. The selection of immunopotentiators can be diverse, including but not limited to checkpoint inhibitors, cytokines or specific antibodies. For example, checkpoint inhibitors can block the mechanism by which cancer cells use immune checkpoints to evade the immune system, cytokines such as interleukins or interferons can enhance the activity of immune cells, and specific antibodies can directly target and neutralize key proteins on the surface of cancer cells.
[0042] It not only enhances the targeted killing ability of stem cells, but also provides patients with a multi-level defense mechanism by synergistically activating the host immune response. Through these comprehensive in vitro evaluations, the predictability and safety of treatment strategies can be greatly improved, laying a solid foundation for subsequent clinical applications.
[0043] After the introduced stem cells in step S4 are verified to be effective, they are tested for efficacy and safety in animal models. The test content includes the evaluation of cell migration, localization, proliferation and long-term survival ability in the body. The interaction between stem cells and the cancer cell microenvironment in step S4 is not limited to hypoxia or specific cytokines, but also includes responses to unique metabolites released by cancer cells. These metabolites, such as lactate and growth factors, can serve as activation signals to further activate proliferation and cytotoxic programs in stem cells.
[0044] Among them, after the gene-edited stem cells are successfully verified in vitro in step S4, comprehensive efficacy and safety tests are required in animal models. This test is mainly aimed at evaluating the performance of stem cells in actual organisms to ensure that their therapeutic potential can be realized in more complex biological systems and will not cause adverse reactions.
[0045] The specific contents of animal model testing include:
[0046] Cell migration and localization ability: Testing whether stem cells can effectively migrate to specific parts of cancer tissue is the key to evaluating the effectiveness of targeted therapy. The effectiveness of treatment depends largely on whether stem cells can accurately identify and reach the location of cancer cells;
[0047] Cell proliferation capacity: evaluates whether stem cells can effectively proliferate in the microenvironment once they are located in cancer tissues, so as to continuously exert killing pressure on cancer cells;
[0048] Long-term viability: monitoring the survival time of stem cells in the body to ensure that they can remain in the host for a long time, thereby providing a sustained therapeutic effect;
[0049] Safety assessment: observe whether stem cells induce any adverse reactions in the body, such as immune rejection or adverse proliferation of other tissues;
[0050] The design of stem cells not only enables them to target cancer cells, but also respond to microenvironmental signals unique to cancer cells, such as hypoxia and specific cytokines. Stem cells are also responsive to metabolites released by cancer cells, such as lactic acid and various growth factors. These metabolites are common in cancer tissues and can serve as activation signals to further activate proliferation and cytotoxicity programs in stem cells, making stem cells more active in the cancer microenvironment and improving their attack efficiency and durability on cancer cells.
[0051] Through these comprehensive tests and unique designs, Step S4 ensures that stem cell therapy is not only effective in theory and in vitro experiments, but can also safely and effectively perform its anti-cancer function in actual organisms, providing a solid foundation for subsequent clinical trials and eventual patient applications.
[0052] It will be apparent to those skilled in the art that the invention is not limited to the details of the exemplary embodiments described above and that the invention can be implemented in other specific forms without departing from the spirit or essential features of the invention. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations falling within the meaning and scope of the equivalent elements of the claims be included in the invention. Any reference numeral in a claim should not be considered as limiting the claim to which it relates.
[0053] In addition, it should be understood that although the present specification is described according to embodiments, not every embodiment contains only one independent technical solution. This narrative method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation methods that those skilled in the art can understand.
Claims
1. A stem cell-based cancer targeted therapy strategy, characterized in that: The following steps are involved: S1: Select and extract human mesenchymal stem cells with high proliferation capacity and stable gene expression as stem cells for gene editing; S2: Use CRISPR-Cas9 technology to introduce cancer cell-specific recognition receptor genes and cytotoxic factor genes into stem cells. Cancer cell-specific recognition receptor genes encode receptors that can recognize cancer cell-specific surface proteins and cytotoxic factor genes. Cytotoxic factor genes are activated in the specific microenvironment of cancer cells. S3: Apply edited stem cells to cancer patients to achieve targeted recognition and killing of cancer cells; S4: The introduced stem cells activate the built-in proliferation and cytotoxic programs by interacting with specific signals in the cancer cell microenvironment, such as hypoxia or specific cytokines, thereby enhancing the therapeutic effect.
2. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: When selecting the stem cells in step S1, they are screened by specific biomarkers, such as CD44 or CD133, to ensure their survival in the cancer microenvironment.
3. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: The selection of cancer cell specific recognition receptor genes in step S2 is based on whole genome expression analysis to determine those cancer cell surface proteins that are highly expressed in various cancer tissues and lowly expressed in normal tissues.
4. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: The toxin or protein encoded by the cytotoxic factor gene in step S2 is activated only under specific cancer cell microenvironment conditions, such as low pH or high activation factor concentration, to minimize damage to normal cells.
5. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: The step S2 further includes using CRISPR-Cas9 technology to knock out genes in stem cells that are known to cause tumor formation or reduce the therapeutic effect, so as to improve the safety and effectiveness of the treatment.
6. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: The step S2 further includes biosafety-enhanced editing of stem cells, including introducing a suicide gene through gene editing technology, which can be triggered by external signals under specific conditions, such as light of a specific wavelength or chemicals, to ensure that the function of the stem cells can be safely terminated after treatment or in any abnormal proliferation situation.
7. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: After the stem cells in step S3 are gene-edited, the cancer cell recognition and killing efficiency need to be verified in vitro, including a comprehensive evaluation of the specificity and cytotoxic effects of the edited cells on different cancer cell lines.
8. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: In step S3, the edited stem cells are used in combination with one or more immune enhancers to enhance the immune system's recognition and clearance of cancer cells. The immune enhancers may include but are not limited to checkpoint inhibitors, cytokines or specific antibodies.
9. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: After the stem cells introduced in step S4 are verified to be effective, they are then tested for efficacy and safety in an animal model. The test content includes the evaluation of the migration, localization, proliferation and long-term survival ability of the cells in the body.
10. The stem cell-based cancer targeted therapy strategy according to claim 1, characterized in that: The interaction between stem cells and the cancer cell microenvironment in step S4 is not limited to hypoxia or specific cytokines, but also includes responses to unique metabolites released by cancer cells. These metabolites, such as lactate and growth factors, can serve as activation signals to further activate proliferation and cytotoxic programs in stem cells.
